Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs Meto
Two GLP-1 providers, compared side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
Published by The GLP-1 Verdict
Pricing sources checked: CoreAge Rx: August 2026 · Meto: Check date not recorded
vs
Verdict53/ 100
Grade C · #454Meto
Meto is an insurance-accepting metabolic telehealth platform offering compounded semaglutide and compounded tirzepatide, prescribed after clinician-ordered lab work.
Visit MetoThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 53/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Meto still earns its place — shoppers who want insurance-accepting metabolic telehealth with compounded sema/tirz, lab monitoring, all 50 states.
The score compares published program terms and features; it does not measure clinical outcomes or predict which treatment will suit you.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results69
92
Real-world results69
97Price honesty20
97
Price honesty20
96Prescriber access58
96
Prescriber access58
88Formulary choice40
88
Formulary choice40
95Cancellation fairness56
95
Cancellation fairness56
93Member support84
93
Member support84
Price, coverage & features
| Metric | CoreAge Rx | Meto |
|---|---|---|
| Verdict Score | 94/100 | 53/100 |
| Grade | A | C |
| Semaglutide | $99/mo | Not disclosed |
| Tirzepatide | $149/mo | Not disclosed |
| Coverage | All 50 states | Not disclosed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | No |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Meto
What we like
- Accepts major insurance (Blue Cross, Anthem, United, Aetna) — most patients pay $0–50 per visit
- Requires lab work before prescribing GLP-1s; addresses root-cause metabolic drivers
- Matches patients with endocrinologists and obesity medicine specialists within minutes
- Offers compounded semaglutide and tirzepatide with board-certified physician oversight
- Handles all prior-auth paperwork; provider location pages exist for all 50 US states
The caveats
- Medication pricing fully gated behind quiz — no public cash price for sema or tirz
- Lab panels are a separate out-of-pocket cost ($199–$399) unless covered by insurance
- No LegitScript certification or named compounding pharmacy found on any public page
- Company leadership and clinical team not disclosed publicly
- Self-pay cash pricing exists per site copy but is not published anywhere
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Shoppers who want insurance-accepting metabolic telehealth with compounded sema/tirz, lab monitoring, all 50 states.
Visit Meto Read the full Meto review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programs closest to it, and the same shortlist for Meto does the reverse.
More on CoreAge Rx
More on Meto
Or browse the full comparison hub, every head-to-head A to Z and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.